Alzheimer’s disease is diagnosed through a combination of cognitive testing, brain imaging, and increasingly, biomarker tests that detect the disease’s signature proteins in blood, spinal fluid, or brain scans. The process from first noticing symptoms to receiving a confirmed diagnosis takes an average of 3.5 years, largely because early cognitive changes are often mistaken for normal aging. Here’s what the diagnostic process actually involves and how it has changed in recent years.
Why Symptoms Alone Aren’t Enough
Memory loss, confusion, and difficulty with everyday tasks are the symptoms most people associate with Alzheimer’s. But these same symptoms can be caused by depression, medication side effects, chronic alcohol use, vitamin deficiencies, or other forms of dementia entirely. Revised diagnostic criteria from the Alzheimer’s Association now define the disease as a biological process, not a set of symptoms. That means a clinical presentation alone is not considered diagnostic. Confirming Alzheimer’s requires evidence of the specific brain changes it causes: the buildup of amyloid plaques and tangled tau proteins.
Before pursuing Alzheimer’s-specific testing, doctors first rule out other explanations. Depression is one of the most common mimics, since it can cause significant memory and concentration problems in older adults. Delirium, benzodiazepine use, anti-seizure medications, and alcohol dependence all need to be investigated. Chronic heavy drinking can cause its own forms of brain damage, including thiamine deficiency that leads to a condition called Wernicke-Korsakoff syndrome, which closely resembles dementia.
Cognitive Screening Tests
Most diagnostic workups begin with a brief cognitive screening test, usually in a primary care office. The two most widely used are the MMSE (Mini-Mental State Examination) and the MoCA (Montreal Cognitive Assessment). Both take about 10 to 15 minutes and test memory, attention, language, and spatial reasoning.
The MMSE scores out of 30. A score below 28 distinguishes Alzheimer’s from healthy cognition with 96% sensitivity and 97% specificity. For telling apart mild cognitive impairment (the stage between normal aging and dementia) from full Alzheimer’s, a cutoff score of 25 catches about 77% of true cases. The MoCA, also scored out of 30, uses a cutoff of 23 to separate Alzheimer’s from healthy aging, with similar accuracy (94% sensitivity, 96% specificity). It’s slightly better at detecting mild cognitive impairment, catching 84% of cases at a cutoff of 25.
These tests are a starting point, not a final answer. A low score triggers referral to a specialist, typically at a memory clinic, for more detailed neuropsychological testing and biomarker evaluation.
The Neurological Exam
A neurological exam checks for physical signs that may point toward Alzheimer’s or suggest a different condition. Doctors assess 12 domains including gait, reflexes, coordination, tremor, muscle strength, and cranial nerve function. In Alzheimer’s, the most common physical findings are asymmetrical brisk reflexes, reduced arm swing while walking, subtle tremor, and increased muscle tone. These signs tend to appear as the disease progresses and can help distinguish Alzheimer’s from other neurological conditions that cause dementia, such as Parkinson’s disease or vascular dementia.
Biomarker Tests: The Diagnostic Shift
The biggest change in Alzheimer’s diagnosis over the past decade is the move toward biomarker-based confirmation. Under the current framework, biomarkers are grouped into two tiers.
Core 1 biomarkers detect the earliest biological changes. These include amyloid PET brain scans, approved spinal fluid tests, and blood-based tests that measure specific forms of a protein called phosphorylated tau (particularly p-tau 217). An abnormal result on any Core 1 biomarker is now considered sufficient to establish an Alzheimer’s diagnosis, even in people who have not yet developed symptoms. These markers become abnormal years before memory problems appear, which is why the revised criteria define Alzheimer’s as a process that begins while people are still asymptomatic.
Core 2 biomarkers become abnormal later in the disease. They include tau PET scans and additional fluid-based markers. When abnormal, these provide prognostic information, helping predict how quickly the disease will progress and increasing confidence that Alzheimer’s is the cause of a person’s symptoms rather than a co-existing but unrelated brain condition.
Brain Scans
Two types of PET scans play distinct roles. Amyloid PET scans detect the buildup of amyloid plaques, one of the two hallmark proteins. Tau PET scans, using a tracer called flortaucipir (the first FDA-approved tau tracer), map the location and density of tau tangles, which track more closely with symptom severity. In clinical studies, both types of scan changed doctors’ diagnoses in about 28% of cases and increased diagnostic confidence by roughly 18 to 19%. A negative amyloid PET scan had a particularly strong impact, essentially ruling Alzheimer’s out as the cause of a patient’s symptoms.
Standard MRI scans are also commonly ordered. While they can’t detect amyloid or tau directly, they reveal patterns of brain shrinkage and can rule out other causes of cognitive decline like strokes, tumors, or fluid buildup in the brain.
Blood Tests for Alzheimer’s
For years, confirming Alzheimer’s required either a PET scan (costing thousands of dollars and available only at specialized centers) or a spinal tap. That changed in early 2025, when the FDA cleared the first blood test for diagnosing Alzheimer’s disease. The test measures the ratio of p-tau 217 to a form of amyloid protein in a standard blood sample.
In a clinical study of 499 adults with cognitive symptoms, 91.7% of people who tested positive on the blood test were confirmed to have amyloid plaques by PET scan or spinal fluid testing. Among those who tested negative, 97.3% were confirmed negative by those same reference methods. Less than 20% of patients received an indeterminate result, meaning the test couldn’t clearly call it positive or negative. The test is cleared for adults 55 and older who are already showing signs of cognitive impairment. It’s not a screening tool for people without symptoms.
This blood test is expected to dramatically speed up the diagnostic process by giving primary care doctors a tool to confirm or rule out Alzheimer’s biology without needing a specialist referral for a PET scan or lumbar puncture.
Genetic Testing
Genetic testing plays a limited role in Alzheimer’s diagnosis and is not part of the standard workup for most patients. It is most useful when early-onset Alzheimer’s runs in a family, typically appearing before age 65. In those cases, testing for mutations in three genes (APP, PSEN1, and PSEN2) can confirm a diagnosis of familial Alzheimer’s. If someone with dementia carries a PSEN1 mutation and has supportive brain imaging, the diagnosis is considered confirmed.
For the far more common late-onset, sporadic form of the disease, genetic testing for the APOE-e4 gene variant is not recommended as a diagnostic tool. Carrying one or two copies of APOE-e4 increases your risk of developing Alzheimer’s, but many carriers never develop the disease, and many people with Alzheimer’s don’t carry the variant. The result doesn’t change treatment or confirm a diagnosis.
How Long Diagnosis Takes
A meta-analysis pooling data from 10 studies found that the average time from first symptom awareness to a confirmed dementia diagnosis is 3.5 years. The delay happens at multiple points. Families often attribute early changes to normal aging and don’t seek medical attention for months or years. Once a person does see a primary care doctor, referral to a memory clinic can take additional time. From there, the specialist evaluation itself, including imaging and biomarker testing, adds more weeks or months.
The path typically follows three stages: the gap between symptom onset and first contact with a doctor, the wait between that first visit and a specialist referral, and the time from the specialist visit to a formal diagnosis. Each of these stages can be shortened by recognizing early warning signs and, increasingly, by using blood-based biomarkers that allow faster confirmation without waiting for specialized imaging.